Nascent Biotech, Inc. (OTCMKTS:NBIO) Sees Significant Drop in Short Interest

Nascent Biotech, Inc. (OTCMKTS:NBIO) was the target of a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 1,900 shares, a drop of 85.3% from the June 30th total of 12,900 shares. Based on an average daily volume of 137,200 shares, the days-to-cover ratio is presently 0.0 days.

Nascent Biotech Price Performance

Shares of Nascent Biotech stock traded down $0.01 during trading on Thursday, hitting $0.05. The stock had a trading volume of 94,438 shares, compared to its average volume of 80,125. The firm’s fifty day simple moving average is $0.08 and its 200-day simple moving average is $0.11. Nascent Biotech has a 12 month low of $0.05 and a 12 month high of $0.28.

Nascent Biotech Company Profile

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.